Contact
searchSearch
HMP Global
Login

videos

Ajai Chari, MD
Videos
Bispecific and Trispecific Antibodies Advance Earlier Treatment of Relapsed or Refractory Multiple Myeloma
11/04/2026
Ajai Chari, MD
Ajai Chari, MD, discusses advances in bispecific and trispecific antibody therapy for multiple myeloma, highlighting improved progression-free survival outcomes from recent phase 3 trials, emerging combination regimens, earlier treatment...
Ajai Chari, MD, discusses advances in bispecific and trispecific antibody therapy for multiple myeloma, highlighting improved progression-free survival outcomes from recent phase 3 trials, emerging combination regimens, earlier treatment...
Ajai Chari, MD, discusses...
11/04/2026
Oncology
Mateo Mejia Saldarriaga, MD
Videos
AQUILA Findings Fuel Debate Over Treatment Intensification in High-Risk Smoldering Myeloma
11/04/2026
Mateo Mejia Saldarriaga, MD
Mateo Mejia Saldarriaga, MD, discusses treatment strategies for high-risk smoldering multiple myeloma, highlighting the progression-free survival benefits and limitations of single-agent daratumumab and lenalidomide, findings from the AQUILA...
Mateo Mejia Saldarriaga, MD, discusses treatment strategies for high-risk smoldering multiple myeloma, highlighting the progression-free survival benefits and limitations of single-agent daratumumab and lenalidomide, findings from the AQUILA...
Mateo Mejia Saldarriaga, MD,...
11/04/2026
Oncology
Joseph Mikhael, MD
Videos
Optimizing Treatment Intensity and Dosing in Older and Frail Patients With Multiple Myeloma
11/03/2026
Joseph Mikhael, MD, MEd, FRCPC
Joseph Mikhael, MD, discusses individualized treatment strategies for older and frail patients with multiple myeloma, highlighting comprehensive frailty assessment, dose optimization of lenalidomide, bortezomib, and dexamethasone, and...
Joseph Mikhael, MD, discusses individualized treatment strategies for older and frail patients with multiple myeloma, highlighting comprehensive frailty assessment, dose optimization of lenalidomide, bortezomib, and dexamethasone, and...
Joseph Mikhael, MD, discusses...
11/03/2026
Oncology
Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD
Videos
CAR T-Cell Therapy and Bispecific Antibodies Reshape Treatment Sequencing in Acute Lymphoblastic Leukemia
10/24/2026
Elias Jabbour, MD; Alexandra Gomez Arteaga, MD
Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD, discuss evolving treatment strategies for adult acute lymphoblastic leukemia, highlighting earlier CAR T-cell therapy, advances in bispecific antibodies, MRD-guided treatment selection, and...
Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD, discuss evolving treatment strategies for adult acute lymphoblastic leukemia, highlighting earlier CAR T-cell therapy, advances in bispecific antibodies, MRD-guided treatment selection, and...
Alexandra Gomez-Arteaga, MD, and...
10/24/2026
Oncology
Eunice Wang, MD, and Eytan Stein, MD
Videos
Menin Inhibitors Advance Targeted Treatment Strategies in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia
10/24/2026
Eytan Stein, MD; Eunice S. Wang
Eunice Wang, MD, and Eytan Stein, MD, discuss advances in menin inhibitor therapy for acute myeloid leukemia, highlighting the clinical activity of revumenib and ziftomenib, emerging combination strategies, mechanisms of acquired resistance,...
Eunice Wang, MD, and Eytan Stein, MD, discuss advances in menin inhibitor therapy for acute myeloid leukemia, highlighting the clinical activity of revumenib and ziftomenib, emerging combination strategies, mechanisms of acquired resistance,...
Eunice Wang, MD, and Eytan...
10/24/2026
Oncology
Paul Richardson, MD
Videos
Emerging Immunotherapies and Targeted Agents Advance Treatment of High-Risk Multiple Myeloma
10/24/2026
Paul Richardson, MD
Paul Richardson, MD, discusses advances in high-risk multiple myeloma management, highlighting genomic and functional risk stratification, frontline quadruplet regimens, emerging immunotherapies, and novel CELMoDs such as iberdomide and...
Paul Richardson, MD, discusses advances in high-risk multiple myeloma management, highlighting genomic and functional risk stratification, frontline quadruplet regimens, emerging immunotherapies, and novel CELMoDs such as iberdomide and...
Paul Richardson, MD, discusses...
10/24/2026
Oncology
Pinkal Desai, MD
Videos
MRD-Guided Risk Stratification Refines Transplant Decisions in Patients With Acute Myeloid Leukemia
10/24/2026
Pinkal Desai, MD
Pinkal Desai, MD, discusses post-remission treatment strategies in acute myeloid leukemia, highlighting how molecular risk classification, measurable residual disease monitoring, and transplant-related risk guide allogenic stem cell...
Pinkal Desai, MD, discusses post-remission treatment strategies in acute myeloid leukemia, highlighting how molecular risk classification, measurable residual disease monitoring, and transplant-related risk guide allogenic stem cell...
Pinkal Desai, MD, discusses...
10/24/2026
Oncology
Joshua Richter, MD
Videos
MRD Assessment Advances Risk Stratification and Treatment Decision-Making in Multiple Myeloma
10/24/2026
Joshua Richter, MD
Joshua Richter, MD, discusses the evolving role of measurable residual disease assessment in multiple myeloma, highlighting its prognostic value, growing importance in clinical trials and regulatory decisions, and the need for prospective...
Joshua Richter, MD, discusses the evolving role of measurable residual disease assessment in multiple myeloma, highlighting its prognostic value, growing importance in clinical trials and regulatory decisions, and the need for prospective...
Joshua Richter, MD, discusses...
10/24/2026
Oncology
John Mascarenhas, MD
Videos
JAK Inhibitors and Emerging Combination Strategies Advance Personalized Treatment in Myelofibrosis
10/24/2026
John Mascarenhas, MD
John Mascarenhas, MD, discusses advances in myelofibrosis treatment, highlighting individualized JAK inhibitor selection, emerging CALR-targeted therapies, novel combination strategies involving pelabresib and selinexor, and ongoing efforts...
John Mascarenhas, MD, discusses advances in myelofibrosis treatment, highlighting individualized JAK inhibitor selection, emerging CALR-targeted therapies, novel combination strategies involving pelabresib and selinexor, and ongoing efforts...
John Mascarenhas, MD, discusses...
10/24/2026
Oncology
Catherine Diefenbach, MD
Videos
Optimizing First-Line Treatment Selection Across in Early- and Advanced-Stage Hodgkin Lymphoma
10/15/2026
Catherine Diefenbach, MD
Catherine Diefenbach, MD, discusses evolving first-line treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD, discusses evolving first-line treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD,...
10/15/2026
Oncology

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use